Skip to main content
Dong Shin, MD, Oncology, Atlanta, GA, Emory University Hospital Midtown

DongMShinMDF.A.C.P., F.A.A.A.S.

Oncology • Atlanta, GA

Endocrine Cancer, Head & Neck Cancer, Hematologic Oncology

Professor of Hematology & Medical Oncology, and Francis Kelly Blomeyer Chair in Cancer Research Emory University School of Medicine

Join to view full profile

Dr. Shin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Shin's full profile

Already have an account?

  • Office

    1365 Clifton Rd Ne
    Emory Winship Cancer Institute
    Atlanta, GA 30322
    Phone+1 404-778-1900
    Fax+1 404-778-5520
  • Is this information wrong?

Summary

  • I am a professor of medical oncology focusing on the patient care and research in head and neck cancer and thyroid cancer.
    And I am also a translational physician scientist focusing on drug discovery with nanotechnology and cancer prevention with natural compounds, and biomarker studies. I have had peer reviewed funding over the decades for such research and published more than 390 research articles.

Education & Training

  • University of Texas Health Science Center at Houston/M D Anderson Cancer Center
    University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1985 - 1988
  • Cook County Health and Hospitals System
    Cook County Health and Hospitals SystemResidency, Internal Medicine, 1982 - 1985
  • Yonsei University College of Medicine
    Yonsei University College of MedicineClass of 1975

Certifications & Licensure

  • GA State Medical License
    GA State Medical License 2003 - 2025
  • CA State Medical License
    CA State Medical License 2012 - 2024
  • PA State Medical License
    PA State Medical License 2001 - 2004
  • TX State Medical License
    TX State Medical License 1987 - 2003
  • IL State Medical License
    IL State Medical License 1983 - 1987
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Member of EUAS European Union of Academy of Science, 2018
  • FAAAS American Association of Advancement of Science, 2016
  • KBS Global Award in Science and Technology Korea Broadcasting System (KBS), 2015
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Concurrent Chemoradiotherapy with Weekly Versus Triweekly Cisplatin in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Comparative Analysis  
    Rathi Pillai, Fadlo R Khuri, Nabil F Saba, Conor Steuer, Suchita Pakkala, Kristin Higgins, Jonathan J Beitler, Suresh S Ramalingam, Brandon Twardy, Kelly Schrapp, Taof..., Head & Neck
  • Interleukin-6/STAT3 Signaling Is Prominent and Associated with Reduced Overall Survival in p16 Negative Oropharyngeal Squamous Cell Carcinoma  
    Nabil F Saba, Dong M Shin, Head and Neck Pathology
  • Article MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation  
    Guojing Zhang, Fadlo R Khuri, Taofeek K Owonikoko, Dan Li, Conor E Steuer, Nabil F Saba, Dong M Shin, Sagar Lonial, ScienceDirect

Lectures

  • Phase 1b study of chemoprevention with green tea polyphenon E (PPE) and epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (Erlotinib) in patients (pts)... 
    ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019

Press Mentions

  • Research Roundup: Recent Grants and Publications for Emory Faculty and Staff
    Research Roundup: Recent Grants and Publications for Emory Faculty and StaffMay 22nd, 2023
  • Shop Talk
    Shop TalkFebruary 10th, 2015
  • New Drug Combination Could Prevent Head and Neck Cancer in High-Risk Patients
    New Drug Combination Could Prevent Head and Neck Cancer in High-Risk PatientsFebruary 19th, 2013
  • Join now to see all

Grant Support

  • Tumor membrane vesicle (TMV) vaccine immunotherapy in head and neck cancerNIH2023–2028
  • Toxicity And Efficacy Of GOLD Nanoparticle Photothermal Therapy In CancerNational Cancer Institute2010–2011
  • Spore In Head And Neck CancerNational Cancer Institute2007–2011
  • Second Primary Tumor Prevention W/Egfr Tkis, COX-2 Inhibitors Head &Neck CancerNational Cancer Institute2007–2011
  • Chemoprevention With Green TEA Polyphenon E (PPE) And Egfr-Tkis In Head And NeckNational Cancer Institute2007–2011
  • Nanotherapeutics: Multifunctional Nanoparticles For Drug Delivery And TargetingNational Cancer Institute2008–2009
  • Chemoprevention Of Head And Neck Cancer With ZD1839 And CelecoxibNational Cancer Institute2007–2008
  • Administration CoreNational Cancer Institute2007
  • Second Primary Tumor Prevention W/Egfr Tkis &Cox-2 Inhibitors In H &N CancerNational Cancer Institute2006
  • Chemoprevention Of The Head And Neck Cancer With Zd1839*National Cancer Institute2005–2006
  • Core--Clinical Support/BiostatisticsNational Institute Of Dental &Craniofacial Research2002–2006
  • Chemoprevention Of Head And Neck CancerNational Cancer Institute2004
  • Randomized Adjuvant Therapy Of Head And Neck CancerNational Cancer Institute2000–2001
  • Randomized Adjuvant Therapy Of Head And Neck CancerNational Cancer Institute1998–1999
  • Adjuvant Biologic Therapy For Stage III/IV Head CancerNational Cancer Institute1997–1998

Professional Memberships

Other Languages

  • Korean

Hospital Affiliations

Dr. Dong Shin, Dr. Dong Shin, MD, Dr. D Shin, Dr. Dong M Shin